Fraser Institute News Release: Counterfeit pharmaceutical drugs put Canadian patients at risk
February 08, 2018 05:00 ET
|
Fraser Institute
VANCOUVER, British Columbia, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Counterfeit pharmaceutical drugs pose a real risk to Canadians because they are showing up in brick-and-mortar pharmacies, not just on...
Fraser Institute Media Advisory: How are Canadians at risk from counterfeit pharmaceuticals? New study coming Thursday, Feb. 8
February 07, 2018 06:00 ET
|
Fraser Institute
VANCOUVER, British Columbia, Feb. 07, 2018 (GLOBE NEWSWIRE) -- On Thursday, Feb. 8, the Fraser Institute will release a new study examining counterfeit pharmaceutical drugs. Pharmaceutical...
Veritas’ Research Arm Cannevert Signs Clinical Research Agreement for Human Studies to Assess its Lead Cannabis Strain for Pain
January 10, 2018 17:02 ET
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to announce that its research arm,...
US Patent Office Acknowledges Provisional Patent Application for Use of Specific Cannabis Strain to Enhance Opioid Analgesia Filed by Veritas’ Research Arm Cannevert
November 28, 2017 03:05 ET
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces its research arm, Cannevert...
Issue Brief Explores the Many Facets of Opioid Abuse
September 14, 2016 07:33 ET
|
The Center for Health Affairs
CLEVELAND, Sept. 14, 2016 (GLOBE NEWSWIRE) -- The Center for Health Affairs' August 2016 Issue Brief, A Growing Epidemic: Battling Opioid Abuse in Ohio, explores the many facets of the opioid abuse...
Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
June 13, 2016 01:18 ET
|
SymBio Pharmaceuticals Ltd
TOKYO, June 13, 2016 (GLOBE NEWSWIRE) -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) announced today that the Phase 3 clinical trial on “SyB P-1501” – a drug for...